) --

BioMimetic Therapeutics



) hit a new 52-week low Monday as it is currently trading at $4.39, below its previous 52-week low of $4.40 with 66,579 shares traded as of 11:10 a.m. ET. Average volume has been 619,200 shares over the past 30 days.

BioMimetic has a market cap of $124.8 million and is part of the

health care

sector and

health services

industry. Shares are down 64.4% year to date as of the close of trading on Friday.

TheStreet Recommends

BioMimetic Therapeutics, Inc., a biotechnology company, engages in the development and commercialization of regenerative protein therapeutic-device combination products for the treatment of musculoskeletal injuries and conditions affecting bones, tendons, ligaments, and cartilage.

  • Practice your BMTI trading strategies and win cash in our stock game.

TheStreet Ratings rates BioMimetic as a


. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. You can view the full

BioMimetic Ratings Report


See all

52-week low stocks

or get investment ideas from our

investment research center